CLEVERCARDS
8.7.2021 17:32:08 CEST | Business Wire | Press release
Giuseppe Di Marco has joined CleverCards as Senior Vice President for Business Development Europe & Managing Director of CleverCards Italia, from Accel and Battery Ventures-backed, mid-market Spend Management leader, Soldo.
Di Marco led and built the Soldo business in Italy after a successful payments career as CEO of ePay Italy (Euronet: EEFT), CEO of the Zucchetti eCommerce and payments services division (Zucchetti is Italian market leader of ERP and HR software), Managing Director of Lottomatica Payments Services Division (LIS & Totobit Servizi) and Head of QuiGroup Payments Service Division.
CleverCards is a leading global payments platform which makes it possible for anyone, anywhere, anytime, to be paid instantly by enabling businesses, governments and public sector organisations to simply send a digital prepaid Mastercard to an email address or mobile phone number by SMS or WhatsApp, empowering the recipients to spend online, or use their mobile in-store contactlessly using Google Pay, Samsung Pay or Apple Pay immediately.
“The US and European B2B payment markets are highly fragmented and CleverCards is planning to consolidate it through an aggressive buy and build acquisition strategy, driving growth and expansion through digital transformation realising its vision of becoming the ubiquitous global payments platform”, says Kealan Lennon, Founder & CEO of CleverCards.
Earlier this year, CleverCards entered into a definitive agreement to acquire ExpendiaSmart®, a market leader in Europe for Spend Management Solutions and Smart Corporate Cards, along with a Licensed, Electronic Money Institution, subject to regulatory approval.
In February this year, Mastercard and CleverCards signed a strategic partnership and development agreement to expand the usage of digital cards across Europe, a FinTech partnership that provides unprecedented, unique access to Mastercard business development teams in key markets and to key commercial clients.
“Our B2B payments platform is growing exponentially, as organisations seek to manage employee, vendor and customer pay-outs on one platform. CleverCards needed someone with an intimate understanding of the payments industry and a demonstrable ability to rapidly scale a Fintech business. In Giuseppe we’ve found that. His track record speaks for itself and we’re very excited about CleverCards continued European expansion,” adds Lennon.
At CleverCards, Giuseppe will build upon the company’s reputation as a market leader in the corporate sector with Spend Management Solutions and Smart Corporate Cards for employees, drivers and contractors, into the Public Sector with digital Mastercards, empowering social welfare recipients to spend online, or use their mobile in-store contactlessly using Google Pay, Samsung Pay or Apple Pay.
Di Marco comments, “The future of payments is digital. While many companies are scrambling to offer individual B2B solutions, none enable large private or public sector organisations to manage employee, vendor, customer or public sector payments on one platform like CleverCards. We’re providing organisations with greater speed, control and flexibility on pay-outs than ever before. I think that’s a really exciting proposition and both organisations and cardholders love it!”
ENDS
ABOUT CLEVERCARDS
Public and private sector organisations of all sizes use the CleverCards payments platform, making it possible for anyone, anywhere, anytime to be paid instantly, regardless of where they are and without the need for a bank account. Empowered with effortless configuration, customised branding and personalisation, along with elegant mobile-first cardholder experiences, CleverCards uses technology to remove numerous unnecessary processes and participants from the payments value chain, delivering unrivalled efficiencies whilst automating the management of all relevant financial services regulations, including KYC and KYB onboarding, AML and PCI DSS compliance. Since launching its payments platform in December 2019, CleverCards has experienced dramatic growth, with over 5,000 large enterprise businesses and public sector organisations already using the platform. For more information visit www.clevercards.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210708005694/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom